Invivyd (IVVD) risk factors

Item 1A of every Invivyd, Inc. 10-K on file, and what changed from one year to the next.

FY2025 10-K risk factors
104 risks, 22 new, 9 dropped, 21 reworded since the prior year. Invivyd added new risks regarding its Silicon Valley Bank loan agreement and cash runway of $226.7 million as of year-end 2025. The company updated figures for its federal and state net operating loss carryforwards and detailed ongoing management transitions.
Filed Mar 05, 2026
FY2024 10-K risk factors
91 risks. Invivyd faces going concern doubts, relying heavily on PEMGARDA's commercial success for revenue and profitability. The company has incurred substantial net losses, reaching $169.9 million in 2024. Operations are heavily dependent on third-party manufacturers like WuXi Biologics and compliance with FDA regulations.
Filed Mar 20, 2025